abstract |
The present invention provides a nanobody targeting RAGE and its application, wherein the complementarity determining region of the amino acid sequence of the nanobody targeting RAGE is CDR1 as shown in SEQ ID NO: 9, and CDR1 as shown in SEQ ID NO: 11 CDR2 shown, CDR3 shown in SEQ ID NO:13. The nanobody of the technical solution of the present invention has strong binding to RAGE, can block the interaction between RAGE and various receptors, and has a therapeutic effect on AD and cancer. |